For leptin and prostate cancer incidence, exclusion of the study by Stocks et al.58) decreased the heterogeneity amongst prospective studies (from 54.9% to 27.4%) but slightly attenuated the affect estimate from 0.97 (0.95–0.99) to 0.98 (0.95–1.00). The gene discussed is LEP; the disease is prostate carcinoma.